| Proteogenomic and metabolomic characterization of human glioblastoma LB Wang, A Karpova, MA Gritsenko, JE Kyle, S Cao, Y Li, D Rykunov, ... Cancer cell 39 (4), 509-528. e20, 2021 | 390 | 2021 |
| Proteogenomic characterization of endometrial carcinoma Y Dou, EA Kawaler, DC Zhou, MA Gritsenko, C Huang, L Blumenberg, ... Cell 180 (4), 729-748. e26, 2020 | 325 | 2020 |
| Integrated proteogenomic characterization across major histological types of pediatric brain cancer F Petralia, N Tignor, B Reva, M Koptyra, S Chowdhury, D Rykunov, A Krek, ... Cell 183 (7), 1962-1985. e31, 2020 | 208 | 2020 |
| The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance SK Joshi, T Nechiporuk, D Bottomly, PD Piehowski, JA Reisz, ... Cancer cell 39 (7), 999-1014. e8, 2021 | 76 | 2021 |
| Residual tissue repositories as a resource for population-based cancer proteomic studies PD Piehowski, VA Petyuk, RL Sontag, MA Gritsenko, KK Weitz, ... Clinical proteomics 15, 1-12, 2018 | 44 | 2018 |
| Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML SJC Gosline, C Tognon, M Nestor, S Joshi, R Modak, A Damnernsawad, ... Clinical proteomics 19 (1), 30, 2022 | 11 | 2022 |
| Children’s Brain Tumor Network; Clinical Proteomic Tumor Analysis Consortium. Integrated proteogenomic characterization across major histological types of pediatric brain cancer F Petralia, N Tignor, B Reva, M Koptyra, S Chowdhury, D Rykunov, A Krek, ... Cell 183 (7), 1962-1985, 2020 | 10 | 2020 |
| Deep-learning-derived evaluation metrics enable effective benchmarking of computational tools for phosphopeptide identification W Jiang, B Wen, K Li, WF Zeng, F da Veiga Leprevost, J Moon, VA Petyuk, ... Molecular & Cellular Proteomics 20, 2021 | 9 | 2021 |
| Proteogenomic insights suggest druggable pathways in endometrial carcinoma Y Dou, L Katsnelson, MA Gritsenko, Y Hu, B Reva, R Hong, YT Wang, ... Cancer cell 41 (9), 1586-1605. e15, 2023 | 7 | 2023 |
| Urine cell-free microRNAs in localized prostate cancer patients Y Koh, MA Bustos, J Moon, R Gross, RI Ramos, S Ryu, J Choe, SY Lin, ... Cancers 14 (10), 2388, 2022 | 6 | 2022 |
| Sensory innervation as a novel driver of ovarian cancer progression M Knarr, K Cummins, D Racordon, H Reavis, T Lippert, R Hausler, ... Cancer Research 84 (6_Supplement), 2922-2922, 2024 | | 2024 |
| Norepinephrine induces anoikis resistance in high-grade serous ovarian cancer precursor cells HD Reavis, SM Gysler, GB McKenney, M Knarr, HJ Lusk, P Rawat, ... JCI insight 9 (5), 2024 | | 2024 |
| Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia JC Pino, C Posso, SK Joshi, M Nestor, J Moon, JR Hansen, ... Cell Reports Medicine 5 (1), 2024 | | 2024 |
| 735 Peripheral and tissue persistence of agenT-797, an allogeneic iNKT cell-based cell therapy for the treatment of cancer J Moon, S Ryu, IR Ramos, B Garmezy, J Hamm, B Carneiro, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Mapping the molecular landscape of acute myeloid leukemia enables prediction of drug response from proteogenomic data JC Pino, C Posso, SK Joshi, M Nestor, J Moon, JR Hansen, MA Gritsenko, ... Cancer Research 83 (7_Supplement), 3172-3172, 2023 | | 2023 |
| Utilizing proteomics and phosphoproteomics to predict ex vivo drug sensitivity across genetically diverse AML patients SJC Gosline, C Tognon, M Nestor, S Joshi, R Modak, A Damnernsawad, ... bioRxiv, 2021.06. 04.447154, 2021 | | 2021 |
| Evolution of Gilteritinib Resistance from Residual Disease to Relapse SK Joshi, T Nechiporuk, D Bottomly, P Piehowski, J Reisz, J Pittsenbarger, ... Blood 136, 4-5, 2020 | | 2020 |
